{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:25:13Z","timestamp":1780611913043,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 HL135273"],"award-info":[{"award-number":["K23 HL135273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.amjcard.2021.10.049","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T11:25:37Z","timestamp":1639221937000},"page":"58-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-0631","authenticated-orcid":false,"given":"Daniel N.","family":"Silverman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-1786","authenticated-orcid":false,"given":"Jeanne du Fay","family":"de Lavallaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-9597","authenticated-orcid":false,"given":"Timothy B.","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-6166","authenticated-orcid":false,"given":"Margaret M.","family":"Infeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-3737","authenticated-orcid":false,"given":"Parag","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Juraschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff B.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3840-4081","authenticated-orcid":false,"given":"Peter W.","family":"Callas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2021.10.049_bib0001","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0002","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/clc.23303","article-title":"Hypertension in older adults: assessment, management, and challenges","volume":"43","author":"Oliveros","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0003","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(08)60655-8","article-title":"Global burden of blood-pressure-related disease, 2001","volume":"371","author":"Lawes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0004","first-page":"2103","article-title":"A randomized trial of intensive versus standard blood-pressure control [Published correction appears in N Engl J Med 2017;377:2506]","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of beta-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006213","article-title":"Heart rate and heart failure with preserved ejection fraction: time to slow beta-blocker use?","volume":"12","author":"Meyer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric casual inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0010","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0011","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0013","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2008.05.057","article-title":"Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis","volume":"52","author":"Bangalore","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0014","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0015","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0016","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/HYPERTENSIONAHA.120.15323","article-title":"Prior beta-blocker therapy for hypertension and sex-based differences in heart failure among patients with incident coronary heart disease","volume":"76","author":"Bugiardini","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0017","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0018","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/HJH.0000000000000848","article-title":"Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure\u2013meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0019","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/MCA.0000000000000610","article-title":"\u03b2-blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction: recommendations, mechanisms, and concerns","volume":"29","author":"Nambiar","year":"2018","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0020","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","article-title":"Association between \u03b2-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry","volume":"27","author":"Meyer","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0021","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cardfail.2019.08.020","article-title":"\u03b2-blocker cessation in stable outpatients with heart failure with a preserved ejection fraction","volume":"26","author":"Nambiar","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0022","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0735-1097(98)00478-1","article-title":"Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study","volume":"32","author":"Luchner","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0025-7125(03)00168-8","article-title":"Cardiac remodeling in systemic hypertension","volume":"88","author":"Kenchaiah","year":"2004","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0026","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"Beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0027","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0028","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/eurheartj\/ehy811","article-title":"\u03b2-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study","volume":"40","author":"Sorbets","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2021.10.049_bib0029","first-page":"291","article-title":"Effect of beta-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis","volume":"16","author":"Malik","year":"2019","journal-title":"J Geriatr Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914921011048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914921011048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:16:10Z","timestamp":1777392970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914921011048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":27,"alternative-id":["S0002914921011048"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.10.049","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.10.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}